SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

22 May 2024 Evaluate
A fair growth of 9.60% in the revenue at Rs. 6176.32 millions was reported in the March 2024 quarter as compared to Rs. 5635.57 millions during year-ago period.The Company's Net profit for the March 2024 quarter have declined marginally to Rs. 536.64  millions as against Rs. 623.97 millions reported during the corresponding quarter ended.A decline of 1204.25 millions was observed in the OP in the quarter ended March 2024 from 1458.13 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 6176.32 5635.57 9.60 21532.58 18544.96 16.11 21532.58 18544.96 16.11
Other Income 296.34 263.78 12.34 723.06 840.66 -13.99 723.06 840.66 -13.99
PBIDT 1204.25 1458.13 -17.41 3275.82 1825.43 79.45 3275.82 1825.43 79.45
Interest 467.66 429.01 9.01 1679.28 1386.82 21.09 1679.28 1386.82 21.09
PBDT 735.85 879.12 -16.30 1542.89 288.61 434.59 1542.89 288.61 434.59
Depreciation 208.07 227.12 -8.39 846.68 936.21 -9.56 846.68 936.21 -9.56
PBT 527.78 652.00 -19.05 696.21 -647.60 -207.51 696.21 -647.60 -207.51
TAX -8.86 28.03 -131.61 41.30 -694.42 -105.95 41.30 -694.42 -105.95
Deferred Tax 19.42 258.12 -92.48 38.18 -195.99 -119.48 38.18 -195.99 -119.48
PAT 536.64 623.97 -14.00 654.91 46.82 1298.78 654.91 46.82 1298.78
Equity 919.00 903.03 1.77 919.00 903.03 1.77 919.00 903.03 1.77
PBIDTM(%) 19.50 25.87 -24.64 15.21 9.84 54.55 15.21 9.84 54.55

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×